Drug Discovery and Early Development Outsourcing Services Industry Analysis - M&As, Partnerships and the Shift Toward an End-to-end CRDMO Model will Boost Sector Expansion - ResearchAndMarkets.com
The "Growth Opportunities in Drug Discovery and Early Development Outsourcing Services" report has been added to ResearchAndMarkets.com's offering.
- The "Growth Opportunities in Drug Discovery and Early Development Outsourcing Services" report has been added to ResearchAndMarkets.com's offering.
- Overall R&D expenditure totals about $276.81 billion, with a slow 2.5% growth between 2023 to 2024.
- This activity is improving the partnership landscape across the global drug discovery and preclinical development industry.
- Last, the larger CROs have developed separate lab testing divisions that allow them to focus on specific drug discovery and preclinical development testing services.